Moreover, SPOP mutation promotes BET inhibitor resistance, and this effect can be reversed by AKT inhibitors, suggesting a role of SPOP (the presence of mutated gene) as a biomarker to stratify PCa patients towards treatment with BET inhibitors [76]. The gene discussed is DNER; the disease is posterior cortical atrophy.